Free Trial

Graybug Vision (GRAY) Competitors

$5.20
+0.04 (+0.78%)
(As of 05/24/2024)

GRAY vs. PMN, BOLT, IPA, VIRX, APRE, SPRB, JAN, BIVI, NNVC, and ENLV

Should you be buying Graybug Vision stock or one of its competitors? The main competitors of Graybug Vision include ProMIS Neurosciences (PMN), Bolt Biotherapeutics (BOLT), ImmunoPrecise Antibodies (IPA), Viracta Therapeutics (VIRX), Aprea Therapeutics (APRE), Spruce Biosciences (SPRB), JanOne (JAN), BioVie (BIVI), NanoViricides (NNVC), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical preparations" industry.

Graybug Vision vs.

Graybug Vision (NASDAQ:GRAY) and ProMIS Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, community ranking, valuation, risk, institutional ownership and earnings.

ProMIS Neurosciences has a consensus target price of $8.00, suggesting a potential upside of 403.14%. Given ProMIS Neurosciences' higher probable upside, analysts clearly believe ProMIS Neurosciences is more favorable than Graybug Vision.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Graybug Vision
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
ProMIS Neurosciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

ProMIS Neurosciences has higher revenue and earnings than Graybug Vision. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Graybug VisionN/AN/A-$35.60M-$24.23-0.21
ProMIS Neurosciences$10K3,014.64-$13.21M-$0.74-2.15

In the previous week, ProMIS Neurosciences had 2 more articles in the media than Graybug Vision. MarketBeat recorded 2 mentions for ProMIS Neurosciences and 0 mentions for Graybug Vision. ProMIS Neurosciences' average media sentiment score of 1.25 beat Graybug Vision's score of 1.05 indicating that ProMIS Neurosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Graybug Vision Positive
ProMIS Neurosciences Positive

Graybug Vision's return on equity of -77.61% beat ProMIS Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Graybug VisionN/A -77.61% -71.34%
ProMIS Neurosciences N/A -2,311.60%-130.13%

Graybug Vision received 14 more outperform votes than ProMIS Neurosciences when rated by MarketBeat users. However, 100.00% of users gave ProMIS Neurosciences an outperform vote while only 50.00% of users gave Graybug Vision an outperform vote.

CompanyUnderperformOutperform
Graybug VisionOutperform Votes
16
50.00%
Underperform Votes
16
50.00%
ProMIS NeurosciencesOutperform Votes
2
100.00%
Underperform Votes
No Votes

Graybug Vision has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, ProMIS Neurosciences has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

49.9% of Graybug Vision shares are held by institutional investors. Comparatively, 50.1% of ProMIS Neurosciences shares are held by institutional investors. 7.9% of Graybug Vision shares are held by insiders. Comparatively, 6.4% of ProMIS Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

ProMIS Neurosciences beats Graybug Vision on 10 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRAY vs. The Competition

MetricGraybug VisionPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$8.17M$6.62B$4.93B$8.08B
Dividend YieldN/A2.77%2.82%3.96%
P/E Ratio-3.0115.27142.3216.35
Price / SalesN/A238.482,489.0072.14
Price / CashN/A20.5032.7728.77
Price / Book3.115.834.934.37
Net Income-$35.60M$138.90M$103.62M$213.15M
7 Day Performance-3.70%-2.66%-1.21%-1.02%
1 Month Performance-4.59%1.18%3.24%3.16%
1 Year Performance68.28%-4.35%4.88%7.23%

Graybug Vision Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PMN
ProMIS Neurosciences
2.8079 of 5 stars
$1.75
+4.2%
$8.00
+358.5%
-65.1%$33.09M$10,000.00-2.366Positive News
Gap Down
BOLT
Bolt Biotherapeutics
2.9076 of 5 stars
$0.79
+2.6%
$3.50
+343.0%
-56.8%$30.12M$7.88M-0.48100Positive News
IPA
ImmunoPrecise Antibodies
3.192 of 5 stars
$1.11
flat
$7.00
+530.6%
-59.9%$29.21M$23.68M-2.71102Positive News
VIRX
Viracta Therapeutics
1.6231 of 5 stars
$0.74
+1.4%
$6.50
+784.4%
-49.7%$28.86MN/A-0.6040Gap Up
APRE
Aprea Therapeutics
3.5306 of 5 stars
$5.30
+5.6%
$15.50
+192.5%
+55.9%$28.77M$580,000.00-1.607Short Interest ↓
Positive News
Gap Down
SPRB
Spruce Biosciences
4.2075 of 5 stars
$0.70
-4.1%
$5.67
+712.4%
-71.3%$28.71M$10.13M-0.6229Short Interest ↓
Positive News
JAN
JanOne
0 of 5 stars
$3.19
+4.6%
N/A+203.8%$28.65M$39.61M0.00199Short Interest ↑
News Coverage
Positive News
Gap Up
BIVI
BioVie
1.7688 of 5 stars
$0.45
-2.2%
$8.00
+1,661.3%
-92.8%$27.72MN/A-0.4818Short Interest ↓
Positive News
High Trading Volume
NNVC
NanoViricides
0 of 5 stars
$2.23
flat
N/A+100.9%$26.34MN/A-2.727Analyst Forecast
ENLV
Enlivex Therapeutics
3.3157 of 5 stars
$1.40
+2.2%
$7.00
+400.0%
-45.7%$26.04MN/A-0.9050Short Interest ↓
News Coverage
Gap Down

Related Companies and Tools

This page (NASDAQ:GRAY) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners